{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:58:53Z","timestamp":1780995533789,"version":"3.54.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s10067-022-06381-y","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T08:03:30Z","timestamp":1663920210000},"page":"269-276","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Combine use of glucocorticoid with other immunosuppressants is a risk factor for Pneumocystis jirovecii pneumonia in autoimmune inflammatory disease patients: a meta-analysis"],"prefix":"10.1007","volume":"42","author":[{"given":"Huyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Shui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4283-9520","authenticated-orcid":false,"given":"Yajuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"key":"6381_CR1","doi-asserted-by":"publisher","unstructured":"Green H, Paul M, Vidal L et al (2007) Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev (3):CD005590. https:\/\/doi.org\/10.1002\/14651858.CD005590.pub2","DOI":"10.1002\/14651858.CD005590.pub2"},{"issue":"1","key":"6381_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jinf.2014.02.015","volume":"69","author":"SJ Kim","year":"2014","unstructured":"Kim SJ, Lee J, Cho YJ et al (2014) Prognostic factors of Pneumocystis jirovecii pneumonia in patients without HIV infection. J Infect 69(1):88\u201395. https:\/\/doi.org\/10.1016\/j.jinf.2014.02.015","journal-title":"J Infect"},{"issue":"7","key":"6381_CR3","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10096-002-0758-5","volume":"21","author":"F Roblot","year":"2002","unstructured":"Roblot F, Godet C, Le Moal G et al (2002) Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis 21(7):523\u2013531. https:\/\/doi.org\/10.1007\/s10096-002-0758-5","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"10","key":"6381_CR4","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1080\/14787210.2019.1671823","volume":"17","author":"C Cill\u00f3niz","year":"2019","unstructured":"Cill\u00f3niz C, Domined\u00f2 C, \u00c1lvarez-Mart\u00ednez MJ et al (2019) Pneumocystis pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients. Expert Rev Anti Infect Ther 17(10):787\u2013801. https:\/\/doi.org\/10.1080\/14787210.2019.1671823","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"RR-4","key":"6381_CR5","first-page":"1","volume":"58","author":"JE Kaplan","year":"2009","unstructured":"Kaplan JE, Benson C, Holmes KK et al (2009) Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 58(RR-4):1\u2013207","journal-title":"MMWR Recomm Rep"},{"issue":"6","key":"6381_CR6","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.berh.2011.11.002","volume":"25","author":"CM Spies","year":"2011","unstructured":"Spies CM, Strehl C, van der Goes MC et al (2011) Glucocorticoids. Best Pract Res Clin Rheumatol 25(6):891\u2013900. https:\/\/doi.org\/10.1016\/j.berh.2011.11.002","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"6","key":"6381_CR7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.resinv.2021.04.011","volume":"59","author":"Y Kondoh","year":"2021","unstructured":"Kondoh Y, Makino S, Ogura T et al (2021) 2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. Respir Investig 59(6):709\u2013740. https:\/\/doi.org\/10.1016\/j.resinv.2021.04.011","journal-title":"Respir Investig"},{"issue":"9398","key":"6381_CR8","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1016\/S0140-6736(03)14904-5","volume":"362","author":"MS Lionakis","year":"2003","unstructured":"Lionakis MS, Kontoyiannis DP (2003) Glucocorticoids and invasive fungal infections. Lancet 362(9398):1828\u20131838. https:\/\/doi.org\/10.1016\/S0140-6736(03)14904-5","journal-title":"Lancet"},{"issue":"5","key":"6381_CR9","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","volume":"77","author":"JW Park","year":"2018","unstructured":"Park JW, Curtis JR, Moon J et al (2018) Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis 77(5):644\u2013649. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211796","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"6381_CR10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s150100070041","volume":"28","author":"T Gl\u00fcck","year":"2000","unstructured":"Gl\u00fcck T, Geerdes-Fenge HF, Straub RH et al (2000) Pneumocystis carinii pneumonia as a complication of immunosuppressive therapy. Infection 28(4):227\u201330. https:\/\/doi.org\/10.1007\/s150100070041","journal-title":"Infection"},{"issue":"162","key":"6381_CR11","first-page":"D2215","volume":"30","author":"TC Minderhoud","year":"2018","unstructured":"Minderhoud TC, van Meer MPA, van Thiel RJ et al (2018) Infecties bij gebruik van glucocortico\u00efden [Infections during glucocorticoid use. Ned Tijdschr Geneeskd 30(162):D2215","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"2","key":"6381_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/RHU.0000000000000215","volume":"21","author":"LC Chew","year":"2015","unstructured":"Chew LC, Maceda-Galang LM, Tan YK et al (2015) Pneumocystis jirovecii pneumonia in patients with autoimmune disease on high-dose glucocorticoid. J Clin Rheumatol 21(2):72\u201375. https:\/\/doi.org\/10.1097\/RHU.0000000000000215","journal-title":"J Clin Rheumatol"},{"issue":"5","key":"6381_CR13","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3109\/10428191003699860","volume":"51","author":"S Kamel","year":"2010","unstructured":"Kamel S, O\u2019Connor S, Lee N et al (2010) High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma 51(5):797\u2013801. https:\/\/doi.org\/10.3109\/10428191003699860","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"6381_CR14","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.11150\/kansenshogakuzasshi1970.73.1123","volume":"73","author":"J Okada","year":"1999","unstructured":"Okada J, Kadoya A, Rana M et al (1999) Efficacy of sulfamethoxazole-trimethoprim administration in the prevention of Pneumocystis carinii pneumonia in patients with connective tissue disease. Kansenshogaku Zasshi 73(11):1123\u20139. https:\/\/doi.org\/10.11150\/kansenshogakuzasshi1970.73.1123","journal-title":"Kansenshogaku Zasshi"},{"issue":"9","key":"6381_CR15","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1111\/j.1365-4632.2010.04857.x","volume":"50","author":"F Li","year":"2011","unstructured":"Li F, Jin HZ, Su F et al (2011) Pneumocystis pneumonia in patients with immunobullous dermatoses. Int J Dermatol 50(9):1144\u20131149. https:\/\/doi.org\/10.1111\/j.1365-4632.2010.04857.x","journal-title":"Int J Dermatol"},{"issue":"3","key":"6381_CR16","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/rheumatology\/keq314","volume":"50","author":"A Mekinian","year":"2011","unstructured":"Mekinian A, Durand-Joly I, Hatron PY et al (2011) Pneumocystis jirovecii colonization in patients with systemic autoimmune diseases: prevalence, risk factors of colonization and outcome. Rheumatology (Oxford) 50(3):569\u2013577. https:\/\/doi.org\/10.1093\/rheumatology\/keq314","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"6381_CR17","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jaad.2009.07.042","volume":"62","author":"JL Gerhart","year":"2010","unstructured":"Gerhart JL, Kalaaji AN (2010) Development of Pneumocystis carinii pneumonia in patients with immunobullous and connective tissue disease receiving immunosuppressive medications. J Am Acad Dermatol 62(6):957\u2013961. https:\/\/doi.org\/10.1016\/j.jaad.2009.07.042","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"6381_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/pl00021707","volume":"15","author":"J Ogawa","year":"2005","unstructured":"Ogawa J, Harigai M, Nagasaka K et al (2005) Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy. Mod Rheumatol 15(2):91\u201396. https:\/\/doi.org\/10.1007\/pl00021707","journal-title":"Mod Rheumatol"},{"issue":"11","key":"6381_CR19","doi-asserted-by":"publisher","first-page":"e78699","DOI":"10.1371\/journal.pone.0078699","volume":"8","author":"K Migita","year":"2013","unstructured":"Migita K, Arai T, Ishizuka N et al (2013) Rates of serious intracellular infections in autoimmune disease patients receiving initial glucocorticoid therapy. PLoS One 8(11):e78699. https:\/\/doi.org\/10.1371\/journal.pone.0078699","journal-title":"PLoS One"},{"issue":"5","key":"6381_CR20","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s10165-006-0502-6","volume":"16","author":"N Iikuni","year":"2006","unstructured":"Iikuni N, Kitahama M, Ohta S et al (2006) Evaluation of Pneumocystis pneumonia infection risk factors in patients with connective tissue disease. Mod Rheumatol 16(5):282\u2013288. https:\/\/doi.org\/10.1007\/s10165-006-0502-6","journal-title":"Mod Rheumatol"},{"issue":"3","key":"6381_CR21","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.semarthrit.2011.05.004","volume":"41","author":"P Vananuvat","year":"2011","unstructured":"Vananuvat P, Suwannalai P, Sungkanuparph S et al (2011) Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. Semin Arthritis Rheum 41(3):497\u2013502. https:\/\/doi.org\/10.1016\/j.semarthrit.2011.05.004","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"6381_CR22","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/art.24283","volume":"61","author":"Y Komano","year":"2009","unstructured":"Komano Y, Harigai M, Koike R et al (2009) Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum 61(3):305\u2013312. https:\/\/doi.org\/10.1002\/art.24283","journal-title":"Arthritis Rheum"},{"issue":"6","key":"6381_CR23","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s10165-012-0615-z","volume":"22","author":"M Tanaka","year":"2012","unstructured":"Tanaka M, Sakai R, Koike R et al (2012) Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors. Mod Rheumatol 22(6):849\u2013858. https:\/\/doi.org\/10.1007\/s10165-012-0615-z","journal-title":"Mod Rheumatol"},{"issue":"6","key":"6381_CR24","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s10165-012-0796-5","volume":"23","author":"K Watanabe","year":"2013","unstructured":"Watanabe K, Sakai R, Koike R et al (2013) Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients. Mod Rheumatol 23(6):1085\u20131093. https:\/\/doi.org\/10.1007\/s10165-012-0796-5","journal-title":"Mod Rheumatol"},{"issue":"7","key":"6381_CR25","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/RHU.0000000000000731","volume":"24","author":"K Yukawa","year":"2018","unstructured":"Yukawa K, Nagamoto Y, Watanabe H et al (2018) Risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis and a prophylactic indication of trimethoprim\/sulfamethoxazole. J Clin Rheumatol 24(7):355\u2013360. https:\/\/doi.org\/10.1097\/RHU.0000000000000731","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"6381_CR26","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1440-1843.2009.01660.x","volume":"15","author":"T Enomoto","year":"2010","unstructured":"Enomoto T, Azuma A, Kohno A et al (2010) Differences in the clinical characteristics of Pneumocystis jirovecii pneumonia in immunocompromized patients with and without HIV infection. Respirology 15(1):126\u2013131. https:\/\/doi.org\/10.1111\/j.1440-1843.2009.01660.x","journal-title":"Respirology"},{"issue":"9","key":"6381_CR27","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/myc.12636","volume":"60","author":"RN Wickramasekaran","year":"2017","unstructured":"Wickramasekaran RN, Jewell MP, Sorvillo F et al (2017) The changing trends and profile of pneumocystosis mortality in the United States, 1999\u20132014. Mycoses 60(9):607\u2013615. https:\/\/doi.org\/10.1111\/myc.12636","journal-title":"Mycoses"},{"issue":"3","key":"6381_CR28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10165-005-0395-9","volume":"15","author":"T Sato","year":"2005","unstructured":"Sato T, Inokuma S, Maezawa R et al (2005) Clinical characteristics of Pneumocystis carinii pneumonia in patients with connective tissue diseases. Mod Rheumatol 15(3):191\u2013197. https:\/\/doi.org\/10.1007\/s10165-005-0395-9","journal-title":"Mod Rheumatol"},{"issue":"9","key":"6381_CR29","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.4065\/82.9.1052","volume":"82","author":"H Green","year":"2007","unstructured":"Green H, Paul M, Vidal L et al (2007) Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 82(9):1052\u20131059. https:\/\/doi.org\/10.4065\/82.9.1052","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"6381_CR30","doi-asserted-by":"publisher","first-page":"CD005590","DOI":"10.1002\/14651858.CD005590.pub3","volume":"2014","author":"A Stern","year":"2014","unstructured":"Stern A, Green H, Paul M et al (2014) Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2014(10):CD005590. https:\/\/doi.org\/10.1002\/14651858.CD005590.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"6381_CR31","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00296-008-0721-6","volume":"29","author":"R Lertnawapan","year":"2009","unstructured":"Lertnawapan R, Totemchokchyakarn K, Nantiruj K et al (2009) Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus. Rheumatol Int 29(5):491\u2013496. https:\/\/doi.org\/10.1007\/s00296-008-0721-6","journal-title":"Rheumatol Int"},{"issue":"7","key":"6381_CR32","first-page":"1186","volume":"23","author":"A Kadoya","year":"1996","unstructured":"Kadoya A, Okada J, Iikuni Y et al (1996) Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis\/dermatomyositis or systemic lupus erythematosus. J Rheumatol 23(7):1186\u20131188","journal-title":"J Rheumatol"},{"issue":"6","key":"6381_CR33","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.semarthrit.2016.09.009","volume":"46","author":"S Tadros","year":"2017","unstructured":"Tadros S, Teichtahl AJ, Ciciriello S et al (2017) Pneumocystis jirovecii pneumonia in systemic autoimmune rheumatic disease: a case-control study. Semin Arthritis Rheum 46(6):804\u2013809. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.09.009","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"6381_CR34","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s10067-019-04557-7","volume":"38","author":"AC Duarte","year":"2019","unstructured":"Duarte AC, Cordeiro A, Fernandes BM et al (2019) Rituximab in connective tissue disease-associated interstitial lung disease. Clin Rheumatol 38(7):2001\u20132009. https:\/\/doi.org\/10.1007\/s10067-019-04557-7","journal-title":"Clin Rheumatol"},{"issue":"9","key":"6381_CR35","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1093\/qjmed\/hcv007","volume":"108","author":"C Sharp","year":"2015","unstructured":"Sharp C, Dodds N, Mayers L et al (2015) The role of biologics in treatment of connective tissue disease-associated interstitial lung disease. QJM 108(9):683\u2013688. https:\/\/doi.org\/10.1093\/qjmed\/hcv007","journal-title":"QJM"},{"issue":"24","key":"6381_CR36","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1001\/jama.2009.880","volume":"301","author":"JA Kovacs","year":"2009","unstructured":"Kovacs JA, Masur H (2009) Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment. JAMA 301(24):2578\u20132585. https:\/\/doi.org\/10.1001\/jama.2009.880","journal-title":"JAMA"},{"issue":"10","key":"6381_CR37","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","volume":"15","author":"M Tomblyn","year":"2009","unstructured":"Tomblyn M, Chiller T, Einsele H et al (2009) Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 15(10):1143\u20131238. https:\/\/doi.org\/10.1016\/j.bbmt.2009.06.019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 4","key":"6381_CR38","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/ajt.12119","volume":"13","author":"SI Martin","year":"2013","unstructured":"Martin SI, Fishman JA (2013) AST infectious diseases community of practice. Pneumocystis pneumonia in solid organ transplantation. Am J Transplant 13(Suppl 4):272\u20139. https:\/\/doi.org\/10.1111\/ajt.12119","journal-title":"Am J Transplant"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06381-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06381-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06381-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T05:13:21Z","timestamp":1672982001000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06381-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["6381"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06381-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,23]]},"assertion":[{"value":"7 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}